| URN | urn:agi-llid:867 |
|---|---|
| Total Entities | 0 |
| Connectivity | 1358 |
| Name | CBL |
| Description | similar to CBL E3 ubiquitin protein ligase (Signal transduction protein CBL) (predicted) |
| Notes | The cbl oncogene was first identified as part of a transforming retrovirus which induces mouse pre-B and pro-B cell lymphomas. As an adaptor protein for receptor protein-tyrosine kinases, it positively regulates receptor protein-tyrosine kinase ubiquitination in a manner dependent upon its variant SH2 and RING finger domains. Ubiquitination of receptor protein-tyrosine kinases terminates signaling by marking active receptors for degradation. |
| GO Molecular Function | signal transducer activity |
|---|---|
| sequence-specific DNA binding transcription factor activity | |
| ligase activity | |
| ubiquitin-protein ligase activity | |
| ephrin receptor binding | |
| SH3 domain binding | |
| phosphotyrosine binding | |
| metal ion binding | |
| calcium ion binding | |
| zinc ion binding |
| GO Cellular Component | membrane |
|---|---|
| flotillin complex | |
| plasma membrane | |
| cytoplasm | |
| cytosol | |
| nucleus |
| GO Biological Process | cell surface receptor signaling pathway |
|---|---|
| positive regulation of phosphatidylinositol 3-kinase signaling | |
| negative regulation of epidermal growth factor receptor signaling pathway | |
| fibroblast growth factor receptor signaling pathway | |
| epidermal growth factor receptor signaling pathway | |
| negative regulation of apoptotic process | |
| regulation of signaling | |
| positive regulation of receptor-mediated endocytosis | |
| regulation of transcription, DNA-templated | |
| protein ubiquitination |
| Pathway | Mechanism of Cetuximab Resistance in Colorectal Cancer |
|---|---|
| Chronic Myeloid Leukemia Overview | |
| Natural Killer Cell Activation through ITAM-Containing Receptors | |
| Natural Killer Cell Inhibitory Receptor Signaling | |
| Central T-cell Tolerance | |
| Natural Killer Cell Activation | |
| Cancer Overview | |
| Osteoclast Activation in Gout | |
| Osteoclast Activation in Rheumatoid Arthritis | |
| TNFRSF5/13B -> NFATC1 signaling | |
| MacrophageR -> CEBPB/NF-kB signaling | |
| CD40LG/NF-kB/ELK-SRF/CREB/NFATC Expression Targets | |
| TNFSF13B Expression Targets | |
| ICAM1 Expression Targets | |
| Fibrinogen Expression Targets | |
| scatter factor-hepatocyte growth factor signaling pathway | |
| epidermal growth factor/neuregulin signaling pathway |
| Group | CBL |
|---|---|
| Ubiquitin-dependent protein degradation | |
| Oncogenes | |
| cell surface receptor signaling pathway | |
| signal transducer activity | |
| positive regulation of phosphatidylinositol 3-kinase signaling | |
| negative regulation of epidermal growth factor receptor signaling pathway | |
| fibroblast growth factor receptor signaling pathway | |
| epidermal growth factor receptor signaling pathway | |
| negative regulation of apoptotic process | |
| regulation of signaling | |
| positive regulation of receptor-mediated endocytosis | |
| regulation of transcription, DNA-templated | |
| sequence-specific DNA binding transcription factor activity | |
| ligase activity | |
| ubiquitin-protein ligase activity | |
| protein ubiquitination | |
| ephrin receptor binding | |
| SH3 domain binding | |
| phosphotyrosine binding | |
| metal ion binding | |
| calcium ion binding | |
| zinc ion binding | |
| membrane | |
| flotillin complex | |
| plasma membrane | |
| cytoplasm | |
| cytosol | |
| nucleus | |
| Disease Genes Identified in Syndromic Epilepsy | |
| Secreted proteins | |
| Biofluids assayable substances |
| Source | Curated |
|---|
| LocusLink ID | 867 |
|---|---|
| 12402 | |
| 500985 |
| Cell Localization | Cytoplasm |
|---|---|
| Cell membrane | |
| Nucleus |
| GO ID | 0017124 |
|---|---|
| 0005509 | |
| 0046875 | |
| 0001784 | |
| 0003700 | |
| 0004871 | |
| 0004842 | |
| 0008270 | |
| 0007166 | |
| 0007173 | |
| 0008543 | |
| 0043066 | |
| 0042059 | |
| 0014068 | |
| 0048260 | |
| 0016567 | |
| 0006355 | |
| 0005737 | |
| 0005829 | |
| 0016600 | |
| 0005634 | |
| 0005886 | |
| 0016874 | |
| 0046872 | |
| 0023051 | |
| 0016020 | |
| 0005515 | |
| 0006512 | |
| 0007242 |
| Alias | CBL2 |
|---|---|
| NSLL | |
| C-CBL | |
| RNF55 | |
| FRA11B | |
| E3 ubiquitin-protein ligase CBL | |
| oncogene CBL2 | |
| proto-oncogene c-Cbl | |
| RING finger protein 55 | |
| signal transduction protein CBL | |
| casitas B-lineage lymphoma proto-oncogene | |
| fragile site, folic acid type, rare, fra(11)(q23.3) | |
| Cas-Br-M (murine) ecotropic retroviral transforming sequence | |
| cbl | |
| Cbl-2 | |
| 4732447J05Rik | |
| RGD1561386 | |
| Cbl proto-oncogene, E3 ubiquitin protein ligase | |
| Casitas B-lineage lymphoma | |
| Signal transduction protein CBL (Proto-oncogene c-CBL) | |
| transforming protein (cbl) | |
| protooncogene protein c cbl | |
| proto-oncogene proteins c-cbl | |
| LOC283153 | |
| Cas-Br-M ecotropic retroviral transforming sequence | |
| CBL_HUMAN | |
| cCBL | |
| 4732447J05 | |
| hypothetical protein LOC283153 | |
| similar to CBL E3 ubiquitin protein ligase (Signal transduction protein CBL) (predicted) |
| Mouse chromosome position | 9 24.72 cM |
|---|---|
| 9 26.0 cM |
| OMIM ID | 165360 |
|---|---|
| 613563 |
| Rat chromosome position | 8q22 |
|---|
| Hugo ID | 1541 |
|---|
| Human chromosome position | 11q23.3 |
|---|
| Swiss-Prot Accession | P22681 |
|---|---|
| P22682 | |
| D3ZV15 | |
| Q3U527 | |
| Q8CEA1 | |
| A3KMP8 | |
| Q8NAQ6 |
| PIR ID | B43817 |
|---|---|
| A43817 |
| Unigene ID | Hs.504096 |
|---|---|
| Mm.266871 | |
| Rn.35589 |
| KEGG ID | hsa:867 |
|---|---|
| mmu:12402 | |
| rno:500985 |
| Swiss-Prot ID | CBL_MOUSE |
|---|---|
| CBL_HUMAN |
| EC Number | 6.3.2.- |
|---|
| Ensembl ID | ENSG00000110395 |
|---|---|
| ENSP00000264033 | |
| ENST00000264033 | |
| ENSMUSG00000034342 | |
| ENSMUSP00000041902 | |
| ENSMUST00000037644 |
| Homologene ID | 3802 |
|---|
| Organism | Homo sapiens |
|---|---|
| Mus musculus | |
| Rattus norvegicus |
| MGI ID | 88279 |
|---|
| RGD ID | 1561386 |
|---|
| MedScan ID | 867 |
|---|